| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/14/2011 | US20110172227 Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same |
| 07/14/2011 | US20110172223 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers |
| 07/14/2011 | US20110172219 Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors |
| 07/14/2011 | US20110172218 Cgrp antagonists |
| 07/14/2011 | US20110172211 Transnasal Anticonvulsive Pharmaceutical Composition Comprising Poorly Soluble Anticonvulsant |
| 07/14/2011 | US20110172210 Method for titrating clozapine |
| 07/14/2011 | US20110172209 3h-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of gpr81 receptor disorders |
| 07/14/2011 | US20110172208 Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition |
| 07/14/2011 | US20110172206 Compositions and methods for treatment of neurodegenerative disease |
| 07/14/2011 | US20110172205 Monocyclic amide cgrp receptor antagonists |
| 07/14/2011 | US20110172204 Compounds and their use |
| 07/14/2011 | US20110172202 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| 07/14/2011 | US20110172195 Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
| 07/14/2011 | US20110172191 Thieno-pyridine derivatives as mek inhibitors |
| 07/14/2011 | US20110172190 Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| 07/14/2011 | US20110172188 Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs |
| 07/14/2011 | US20110172186 Inhibitors of fatty acid amide hydrolase |
| 07/14/2011 | US20110172172 Method of Treating Neurological Conditions with Cardiac Glycoside |
| 07/14/2011 | US20110172171 Taurine or taurine-like substances for the prevention of brain oedema |
| 07/14/2011 | US20110172170 Interferon-like protein zcyto21 |
| 07/14/2011 | US20110172159 Proteic acid polymer, production processes, use of proteic acid polymer, pharmaceutical composition and method of treatment |
| 07/14/2011 | US20110172158 Targets, methods, and reagents for diagnosis and treatment of schizophrenia |
| 07/14/2011 | US20110172143 Method of modulating cell survival and reagents useful for same |
| 07/14/2011 | US20110172141 Process for preparing microparticles |
| 07/14/2011 | US20110172114 Compositions and methods for the treatment of immune related diseases |
| 07/14/2011 | US20110171607 Biopulp |
| 07/14/2011 | US20110171329 Method for treatment of neural injuries |
| 07/14/2011 | US20110171302 Method for treating neurodegenerative disorders with oral dosage formulation containing both immediate-release and sustained-release drugs |
| 07/14/2011 | US20110171297 Sustained release formulation for venlafaxine hydrochloride |
| 07/14/2011 | US20110171292 Peptide compositions and methods of use |
| 07/14/2011 | US20110171291 Pathologically-activated therapeutics |
| 07/14/2011 | US20110171275 Gastroretentive drug delivery system, preparation method and use thereof |
| 07/14/2011 | US20110171272 Urological medical devices for release of prostatically beneficial therapeutic agents |
| 07/14/2011 | US20110171270 Novel solid state forms of laquinimod and its sodium salt |
| 07/14/2011 | US20110171265 Composition Comprising Parasite Eggs and Methods for Isolation and Storage of Parasite Eggs |
| 07/14/2011 | US20110171257 Herpes simplex virus amplicon vectors derived from primary isolates |
| 07/14/2011 | US20110171243 Compounds for treating amyloidoses |
| 07/14/2011 | US20110171230 Method of Identifying Agents that Promote Axonal Development |
| 07/14/2011 | US20110171226 Novel Subtype of Closteridium Botulinum Neurotoxin Type A and Uses Thereof |
| 07/14/2011 | US20110171218 Compositions and methods for increasing serum half-life |
| 07/14/2011 | US20110171205 Novel 15571, 2465, 14266, 2882, 52871, 8203 and 16852 molecules and uses therefor |
| 07/14/2011 | US20110171199 Method for reducing or eliminating pain associated with a post-operative wound |
| 07/14/2011 | US20110171197 Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same |
| 07/14/2011 | US20110171194 METHODS AND COMPOSITIONS FOR INHIBITING ABAD/ABeta PROTEIN INTERACTION |
| 07/14/2011 | US20110171186 Chondrocyte therapeutic delivery system |
| 07/14/2011 | US20110171176 Complement antagonists and uses thereof |
| 07/14/2011 | US20110171165 Polymer conjugates of opioid growth factor peptides |
| 07/14/2011 | US20110171141 Administration of dihydroergotamine mesylate particles using a metered dose inhaler |
| 07/14/2011 | US20110171136 Optical imaging probes |
| 07/14/2011 | US20110171131 Method of Altering Perception of Time |
| 07/14/2011 | US20110171128 Aprotinin polypeptides for transporting a compound across the blood-brain barrier |
| 07/14/2011 | DE102010004431A1 Pathogenesis of migraine, which is the causal therapy in the removal of perivascular edema of the dura-vascular of the brain using acetazolamide to treat migraine pain |
| 07/14/2011 | CA2786598A1 Topical transdermal dexmedetomidine compositions and methods of use thereof |
| 07/14/2011 | CA2786072A1 Sulfone compounds as 5-ht6 receptor ligands |
| 07/14/2011 | CA2786019A1 Plasma kallikrein binding proteins |
| 07/14/2011 | CA2785876A1 Novel benzoic pyrrolopyridine derivatives |
| 07/14/2011 | CA2784744A1 Compound |
| 07/14/2011 | CA2784667A1 Mglu2 agonists |
| 07/14/2011 | CA2782347A1 Quinoline amide m1 receptor positive allosteric modulators |
| 07/13/2011 | EP2343316A1 Ligand binding site of RAGE and uses thereof |
| 07/13/2011 | EP2343308A2 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 07/13/2011 | EP2343293A1 Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of t-cell proliferation and uses thereof |
| 07/13/2011 | EP2343275A2 Process for the preparation and crystalline form I of the optical enantiomers of modafinil |
| 07/13/2011 | EP2343078A1 Light-stabilized pharmaceutical composition |
| 07/13/2011 | EP2343077A1 Derivatives of totally N-desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 07/13/2011 | EP2343075A1 Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease |
| 07/13/2011 | EP2343073A2 Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| 07/13/2011 | EP2343069A1 Heterocyclic aspartyl protease inhibitors |
| 07/13/2011 | EP2343068A2 Treatment of length dependent neuropathy |
| 07/13/2011 | EP2343065A1 The pharmaceutical composition containing ferulic acid and matrine compounds, the preparation and the use thereof |
| 07/13/2011 | EP2343064A1 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| 07/13/2011 | EP2343062A1 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 07/13/2011 | EP2343060A1 Multi-layer controlled-release tablet comprising an active layer and one or more barrier layers |
| 07/13/2011 | EP2343057A1 Method and composition for administering an NMDA receptor antagonist to a subject |
| 07/13/2011 | EP2342979A2 Composition for improving membrane composition and functioning of cells |
| 07/13/2011 | EP2342203A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 07/13/2011 | EP2342199A2 Compounds which selectively modulate the cb2 receptor |
| 07/13/2011 | EP2342192A2 Nicotinic acetylcholine receptor ligands and the uses thereof |
| 07/13/2011 | EP2342182A1 Isoquinolinone derivatives as nk3 antagonists |
| 07/13/2011 | EP2341919A1 Cgrp receptor antagonists |
| 07/13/2011 | EP2341912A2 Method of treatment of attention deficit/hyperactivity disorder (adhd) |
| 07/13/2011 | EP2341910A1 Immediate release dosage forms of sodium oxybate |
| 07/13/2011 | EP2341909A1 Novel substituted azabenzoxazoles |
| 07/13/2011 | EP2341904A1 Methods for treatment of multiple sclerosis |
| 07/13/2011 | EP2341903A1 Cannabinoids for use in treating or preventing cognitive impairment and dementia |
| 07/13/2011 | EP2252263B1 Galenic form for the oral transmucosal delivery of triptans |
| 07/13/2011 | EP2200985B1 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
| 07/13/2011 | EP1931683B1 Fused tricyclic mglur1 antagonists as therapeutic agents |
| 07/13/2011 | EP1860185B1 Screening method |
| 07/13/2011 | EP1725537B1 Novel compounds as opioid receptor modulators |
| 07/13/2011 | EP1509489B1 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 07/13/2011 | EP1486491B1 Carboxylic acid compounds and drugs containing the compounds as the active ingredient |
| 07/13/2011 | EP1432420B1 Benzimidazolidinone derivatives as muscarinic agents |
| 07/13/2011 | EP1289553B1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 07/13/2011 | EP1265878B1 A process for the preparation of epothilone analogs and intermediates |
| 07/13/2011 | EP1178825B1 Adjuvant combination formulations |
| 07/13/2011 | EP1178796B1 Orazamide orotate for the prevention of liver damage |
| 07/13/2011 | CN1872216B Medication composition for treating headache, and preparation method |
| 07/13/2011 | CN1826338B Therapeutic agent for senile dementia |
| 07/13/2011 | CN1353609B Amide substituted imidazoquinolines |